Protein downstream process development involves purification, isolation, and characterization of target products from complex biological matrices to ensure that the final product is safe, effective, and of high quality. With years of experience in providing satisfactory downstream process development solutions to each customer, CD Formulation's team of process experts will perform many unit operations and provide you with high-quality downstream process development services by adopting various protein purification and preparation technologies. Whether you are seeking downstream purification process development for small-scale, preclinical evaluation and proof-of-concept studies, or clinical or commercial-scale processes that comply with cGMP, our team of experts can provide you with customized solutions.
Downstream processing (DSP) is a series of unit operations that occur after cell growth and expansion are complete and the production or synthesis of the drug substance or other ingredients is complete. Therapeutic protein downstream processing refers to the recovery and purification of the drug substance from its natural source (e.g., animal or bacterial cells). The main goal of downstream process development is to obtain a drug product with the desired purity, efficacy, and reasonable unit cost, which involves isolating the target protein from the mixture while removing any contaminants that may interfere with its intended use. This stage is a critical step to ensure that the drug candidate does not contain any impurities and obtains adequate yield from the extraction. The process includes isolation, purification, concentration, and formulation.
Fig.1 The flow of downstream process development for therapeutic protein. (CD Formulation)
CD Formulation has extensive experience developing purification processes for multiple types of protein therapeutics, including recombinant proteins, monoclonal antibodies, enzymes, Fc-fusion proteins, bispecific antibodies, and antibody-drug conjugate products. Our advanced protein characterization capabilities enable critical structure-function studies as well as a variety of product-related impurities, including aggregates, improper modifications, truncated forms, and degradation product assessments.
Our downstream processing team offers a broad range of downstream protein purification process development services in a highly competitive manner. We employ integrated process development services to ensure that we provide you with a reproducible, scalable manufacturing process that accelerates your timeline and reduces risk in your development strategy.
Our downstream capabilities are flexible enough to align with the scale of the upstream process, allowing one upstream process (USP) batch to be purified in a single run without the need for batching.
Many of the protein downstream purification process development services we provide include:
Fig. 2 Therapeutic protein downstream purification process. (CD Formulation)
In downstream process development, our team of process experts always takes a holistic approach, viewing the entire therapeutic protein manufacturing process as a complex interaction of many factors at different stages of production. This holistic philosophy guarantees the development of reproducible, reliable, and efficient processes that meet all regulatory requirements.
We integrate QbD principles and provide development platforms in the following modular approach. You can choose a single or specific module or request the entire therapeutic protein process development package from bench to clinical process validation and optimization.
In purification process development, we develop purification methods using preparative systems that have counterparts on an industrial scale and optimize existing purification methods.
To demonstrate that the obtained product has appropriate quality characteristics, we perform a wide range of physicochemical and biological analyses to support the process development of protein products.
Published Data
Technology: Purification processes development for bispecific antibodies.
Journal: MAbs.
IF: 5.6
Published: 2016
Results:
The authors successfully developed a scalable bsAb C purification process to determine the feasibility of purifying star-substituted bispecific antibodies. The results showed that the purity of the bispecific antibody exceeded 95% within a robust operating space.
Fig. 3 Flow scheme of suggested purification processes for star substitution containing bispecific antibodies exhibiting (A) and not exhibiting (B) VH domain SpA binding. (Tustian AD, et al., 2016)
CD Formulation is dedicated to meeting your specific needs for protein purification process development and provides guiding regulatory requirements, process scale-up, and technology transfer, ensuring a seamless transition from development to manufacturing. Please don't hesitate to contact us if you are interested in our services. We look forward to cooperating with you.
References